TV, Film, Broadway Actress Barbara Barrie Discloses She Has

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TV, Film, Broadway Actress Barbara Barrie Discloses She Has Incurable Lung Disease Days Ahead of FDA's First Workshop Focused on Idiopathic Pulmonary Fibrosis

NEW YORK, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Actress Barbara Barrie is sharing her story as an Idiopathic Pulmonary Fibrosis (IPF) patient by speaking out for the first time about her diagnosis with the incurable lung disease.   Barrie is best known for her on Broadway roles in The Selling of the President, The Prisoner of Second Avenue, California Suite, Torch Song Trilogy and Company, TV roles in Suddenly Susan and Barney Miller and guest star appearances most recently in Nurse Jackie and Law & Order, and film roles in One Potato, Two Potato, Frame of Mind, Hercules and Private Benjamin.

Barrie chose to go public during National PF Awareness Month to help raise visibility of the disease and the efforts of the non-profit organization, the Coalition for Pulmonary Fibrosis.  "I have a very full, active life, but what lies ahead is unknown and yet known at the same time," said Barrie who is one of 200,000 Americans living with the disease.  "I am living full steam ahead and am now trying to help other people do the same."

"There has never been a time when IPF has been at the forefront of science and innovation as it is now and having Barbara's voice aligned with our efforts is making a huge difference," said Mishka Michon, CEO of the CPF.  "Her attitude is positive and her words are incredibly inspiring."

Barrie's announcement comes just days ahead of one of the most important meetings for the disease being held at the U.S. Food and Drug Administration (FDA) on Friday.  

The FDA will hold the first IPF Workshop to hear from patients and family members about their experience with the disease.  Barrie submitted her written testimony to the FDA in recent weeks.  She plans to join the workshop via a webinar from her home in New York City.  The FDA is meanwhile reviewing two possible treatments for IPF, InterMune's pirfenidone and Boehringer Ingelheim's nintedanib.  If approved, they will be the first drugs available for IPF patients in the U.S.

IPF causes progressive and relentless scarring in the lungs and renders them unable to exchange life sustaining blood oxygen. "Idiopathic" means the disease has no known cause.  IPF is invariably fatal with a life expectancy of an average three years and claims as many lives each year as breast cancer (40,000).  The only known way to survive the disease longer term is by lung transplantation.  Less than one percent of the patients receive a transplant.  

"Idiopathic pulmonary fibrosis is a devastating disease that does not yet have an FDA-approved treatment," said American Thoracic Society Executive Director Steve Crane, PhD, MPH.  "Having a star such as Ms. Barrie bring attention to this low-profile but deadly disease by personally disclosing her battle with it will help raise much-needed awareness."

Public Figures Lost to Pulmonary Fibrosis include:  Actor/Singer Robert Goulet, Actor Marlon Brando, Actor Gordon Jump from WKRP in Cincinnati, Actor James Doohan from Star Trek, as well as Jaws Author Peter Benchley, and Stuntman Evel Knievel.  

Barrie is available to the media for interviews.  Please contact Teresa Barnes at tbarnes@CoalitionForPF.org to arrange an interview.

About Barbara Barrie:

Barbara Barrie has had a distinguished career in film, television and theatre.  On Broadway, Ms. Barrie has appeared in The Selling of the President, The Prisoner of Second Avenue, California Suite, Torch Song Trilogy, and Company, which garnered her a Tony nomination for Best Performance by an Actress in a Featured Role.  She recently appeared Off-Broadway in I Remember Mama, receiving an Outer Critics Circle award nomination for Outstanding Featured Actress in a Play. Other Off-Broadway credits include The Vagina Monologues, Current Events, After-Play, The Crucible, The Beaux' Stratagem, Love Letters, Isn't It Romantic? and in The Killdeer, for which she earned an Obie and Drama Desk award for Outstanding Off-Broadway Performance.  She has also performed often for both the New York Shakespeare Festival and the American Shakespeare Festival in Stratford, Connecticut.

On television, Ms. Barrie's appearances on Law and Order and Law and Order: Special Victims Unit, earned her an Emmy award nomination for Outstanding Supporting Actress in a Drama Series and a nomination for Outstanding Guest Actress in a Drama Series, respectively.  She earned another Emmy Award nomination for Outstanding Supporting Actress in a Drama Series for her role as 'Evelyn Stoller' in Breaking Away.  She may be best known to television audiences for her regular role in Suddenly Susan opposite Brooke Shields and her recurring and guest star roles in Enlightened, Nurse Jackie,  Once and Again, Barney Miller, Thirtysomething and Family Ties.  Additionally, Ms Barrie's mini-series and television movie credits include Scarlett and Roots: The Next Generation as well as A Chance of Snow, My Left Breast, The Odd Couple: Together Again, Tell Me My Name, To Race the Wind, American Love Affair, and Barefoot in the Park.

Ms. Barrie earned the Best Actress Award in the Cannes Film Festival for her performance in One Potato, Two Potato.  For the film Breaking Away, she earned an Academy Award nomination for Best Performance by an Actress in a Supporting Role. Her performance in the award-winning film Judy Berlin brought her an Independent Spirit Award nomination for Best Supporting Female.  Her other film credits include Frame of Mind, Second Best, Hercules, Private Benjamin, The Bell Jar, and Thirty Days.

Ms. Barrie is also the author of two critically acclaimed novels for young adults, Lone Star and Adam Zigzag, as well as a memoir documenting her bout with colon cancer entitled Second Act which has been released in its paperback version under the title Don't Die of Embarrassment: Life After Colostomy and Other Adventures.

Background on FDA IPF Workshop

The FDA is planning to hold the first FDA IPF Workshop where it plans to hear directly from patients, family members and caregivers about their struggles with the disease as well as their feedback and suggestions for improved drug development in the disease.  IPF was included as one of the FDA "patient focused drug development program" workshops after the IPF patient community spoke out publicly asking FDA to include the disease and sent 3,000 letters to FDA Commissioner Dr. Margaret Hamburg.  The FDA Workshop will take place at the FDA offices in Silver Spring, MD on September 26th.

September -- National Pulmonary Fibrosis Month

All month, the CPF holds national awareness efforts for the 12th year.  The CPF and the American Thoracic Society will co-host an awareness week for the disease during PF month, the same week as the FDA hearing (September 21-27) and will co-host a patient event with Johns Hopkins Medical Center on September 27th and the CPF will bring patients and advocates to Capitol Hill on September 25th, as well.

About Pulmonary Fibrosis (PF)

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring – known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 200,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis.  Sometimes PF can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).

About the CPF

The CPF is a 501C(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure PF; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of PF issues; and works to improve awareness of PF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 28,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with PF. For more information please visit www.coalitionforpf.org or call (888) 222-8541.
 
Photos accompanying this release are available at:

http://www.globenewswire.com/newsroom/prs/?pkgid=27846

http://www.globenewswire.com/newsroom/prs/?pkgid=27847

Teresa Barnes 303-521-4080

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Madrigal Faces Legal Scrutiny Amid Whistleblower Claims

Updated Category News Views 220

The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...

Continue Reading
Everest Group Faces Major Class Action Deadline Looms

Updated Category News Views 166

Everest Group's Headaches Multiply as Deadline Approaches Well, here we find a classic case of Wall Street drama—Everest Group, Ltd. (NYSE:EG), a company whose troubles would make any trader weary. As of late, it's caught up in a nasty class-action lawsuit with stakes high enough to raise eyebrows from Broadway to Bayou. Investors in Everest better be tuned in, because...

Continue Reading
Tenax Therapeutics Faces Legal Heat After Stock Plunge

Updated Category News Views 125

Investors' Nerves Tested as Tenax Takes a Nosedive Holy smokes! When a biotech company like Tenax Therapeutics, Inc. (NASDAQ: TENX) detonates like a forgotten fireworks stash, investors have every right to get itchy. Tenax’s shocking announcement that their Phase 3 LEVEL trial for TNX-103 flopped has sparked more than just shareholder anxiety. It’s ignited a...

Continue Reading
Tenax Sued: Investors Face Class Action Over TNX-103

Updated Category News Views 140

What Tenax Investors Need to Know Alright, folks, time to pull up a chair and pay attention to what's brewing with Tenax Therapeutics—yeah, we're talking NASDAQ: TENX. The company's head is spinning as it's caught up in a securities class action lawsuit. What's the fuss? The fine print here accuses Tenax of misleading investors about the effectiveness of their product,...

Continue Reading
Aurora Innovation Faces Legal Heat Amid Delays

Updated Category News Views 76

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 58

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
CassTime's AI Solution Eases Global Parts Market Strains

Updated Category News Views 130

Driving Innovation in the Auto Aftermarket When car parts become a global jigsaw puzzle, you need more than wrenches to solve it. Enter CassTime with its AI-driven 'T+D Solution'—a tangible answer to the woes of data matching and repair capability bottlenecks plaguing the automotive aftermarket worldwide. Taming the Global Parts Beast Pull back the curtain on AAPEX 2026...

Continue Reading
AXON Revenue Forecast Cut Spurs Legal Investigation

Updated Category News Views 160

Axon's Revenue Forecast Takes a Hit Listen up, folks. Axon Enterprise, Inc. (NASDAQ: AXON) has stirred the pot, cutting their 2026 revenue forecast faster than you can say "counter-drone deployment." Back in August, they were riding high on their second-quarter call, raising their growth forecast to a cheerful 32%-34%. Fast forward to November, and it's been slashed to...

Continue Reading
Pigeon Unveils Green Innovations at CIIE 2026

Updated Category News Views 187

An International Celebration: Cultural Connections at CIIE Babies have a way of bringing the world together. Every culture has its own quirks and traditions, but the love for a newborn is common ground. Pigeon gets that, and they're putting it on full display at the China International Import Expo (CIIE) in Shanghai. It's their fourth run at this rodeo, and they’re not...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 156

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading

Top 5 Most Recently Viewed Articles

Class Intercom Grows With New Brand Identity

Updated Category News Views 39

Class Intercom's Evolution Reflects a Broader Vision Today's education world ain't what it used to be, and Class Intercom seems to be right in the thick of the transformation. They're not just sticking to their old ways of handling school social media. Nope, they’re expanding their reach with a brand new chapter. The Power of Authentic School Storytelling Class Intercom...

Continue Reading
Reichman Jorgensen Welcomes Expertise of Nathan Mammen as Partner

Updated Category News Views 227

Reichman Jorgensen Welcomes Nathan Mammen to the Team Reichman Jorgensen Lehman & Feldberg LLP (RJLF), an esteemed national trial boutique, proudly announces the addition of Nathan Mammen as a partner in its Washington, D.C. office. Mammen, an accomplished intellectual property litigator and appellate lawyer, brings over two decades of experience to the firm. Experience...

Continue Reading
Tokyo Lifestyle Co., Ltd. Achieves Remarkable Fiscal Growth

Updated Category News Views 164

Tokyo Lifestyle Co., Ltd.'s Impressive Growth Report Tokyo Lifestyle Co., Ltd. (NASDAQ: TKLF), a prominent retailer and wholesaler of Japanese beauty and health products, has announced impressive financial results during the first half of fiscal year 2025. This growth reflects their strategic focus on increasing market presence and profitability despite a competitive...

Continue Reading
Pierre Fitzgibbon Joins Volt-Age Program Advisory Board

Updated Category News Views 212

Pierre Fitzgibbon Appointed to Volt-Age Advisory Board Concordia University’s esteemed Volt-Age program has taken a significant step forward by inviting Pierre Fitzgibbon, who previously served as the Minister for Economy, Innovation, and Energy, to its advisory board. This move aims to leverage Fitzgibbon's extensive experience to steer the strategic direction of the...

Continue Reading
EZCORP Restructures Its Acquisition Strategy for Growth

Updated Category News Views 138

EZCORP's Strategic Shift in Acquisition Plans Recently, EZCORP, Inc. (NASDAQ: EZPW), a premier provider of pawn loans throughout the Americas, made headlines by ending its acquisition deal with Presta Dinero, S.A. de C.V. This pivotal decision involves the cancellation of plans to acquire 53 stores in Mexico, first announced earlier. Leadership's Perspective on the...

Continue Reading